AptarGroup, Inc. (NYSE: ATR) has promoted longtime executive Gael Touya to President and Chief Executive Officer effective September 1, completing a succession process announced in March and placing the former Aptar Pharma president in charge of a global drug-delivery, dispensing and packaging technology business. Touya succeeds Stephan B. Tanda, who led Aptar since 2017 and will remain an adviser through the end of 2026 while also preparing to retire from the board.
Touya has spent more than 30 years inside Aptar and has led businesses across Pharma, Food and Beverage, Beauty and international markets. His most recent role is particularly important because Aptar Pharma has become one of the company’s most strategically valuable businesses, supplying drug-delivery and protection technologies used across areas including biologics, GLP-1 therapies, injectables, nasal medicines, ophthalmic products and vaccines.
He also takes control immediately after Aptar achieved a financial milestone. Second-quarter reported sales increased 6% to $1.03 billion, exceeding $1 billion in a quarter for the first time, while net income reached $88 million and adjusted earnings per share were $1.42. The complication is that adjusted EBITDA margin fell to 20.7% from 22.6%, giving Touya a clear mandate to protect profitability while the company continues investing in higher-growth pharmaceutical and consumer categories.
Why did Aptar choose Gael Touya after more than 30 years inside the company?
Touya gives the board deep continuity without simply selecting a corporate administrator. His career has included leadership of Aptar Pharma, Food and Beverage Europe and business-development responsibilities within skincare and cosmetics, providing direct experience across all three of Aptar’s major operating segments.
That breadth matters because Aptar sells highly specialised components into industries with very different economics. Pharmaceutical customers can require years of validation and regulatory work, while prestige beauty products depend more heavily on consumer trends, brand launches and packaging design. Closures and food-and-beverage applications have another set of pricing, volume and customer dynamics.
An internal CEO who understands those differences may be able to allocate capital more precisely than an outsider who initially views the company simply as a packaging manufacturer.
Touya also inherits direct credibility inside the business that increasingly drives Aptar’s technology narrative. Under his leadership, Aptar Pharma expanded from component supply toward a broader model supporting customers from formulation and clinical development through commercialisation.
Why is Aptar Pharma central to the CEO appointment?
Pharma reported 4% second-quarter sales growth, while underlying core sales increased 1%. Management said performance was affected by emergency-medicine destocking, but after adjusting for that headwind, Pharma delivered high-single-digit core growth.
Demand remained strong across prescription dispensing systems, injectables, consumer healthcare, biologics, GLP-1 applications, vaccines and eye-care products. These categories can be particularly valuable because once a drug developer validates a delivery component or system, switching suppliers can be difficult because of regulatory and technical requirements.
That creates higher barriers to entry than many conventional packaging categories. It also explains why Aptar has directed much of its acquisition activity under Tanda toward pharmaceutical technologies.
Touya’s promotion effectively puts the executive closest to that strategic shift in charge of the entire company.
Why did Aptar’s EBITDA margin fall despite record sales?
Aptar’s adjusted EBITDA margin declined to 20.7% from 22.6% a year earlier even as reported sales reached $1.03 billion. Core sales increased only 1%, meaning a substantial part of reported revenue growth came from acquisitions and currency rather than underlying organic expansion.
Pharmaceutical destocking also created pressure, particularly in emergency medicine. Aptar said those comparisons should become easier by the fourth quarter, while injectables and consumer healthcare remained relatively strong.
The margin decline therefore gives Touya an immediate financial priority. Expanding sales through acquisitions and favourable currency is useful, but shareholders ultimately need growth that produces attractive incremental earnings.
Operational efficiency, price discipline and product mix will become important as Aptar attempts to hold margins above 20% while continuing to invest behind innovation.
Why do GLP-1 drugs matter to a packaging and dispensing company?
GLP-1 therapies have become one of the fastest-growing pharmaceutical categories globally, driving enormous demand for injection systems, components and associated drug-delivery technology. Aptar does not need to own the underlying medicine to benefit from that expansion if pharmaceutical manufacturers use its technologies within commercial delivery systems.
The same logic extends to biologics and vaccines. Complex medicines often require specialised containment, delivery and protection systems capable of maintaining product integrity across manufacturing, transportation and patient use.
That gives Aptar exposure to pharmaceutical growth without assuming the binary clinical-development risk faced by drug developers. Its economics depend more on customer wins, volumes and manufacturing execution once therapies reach commercial scale.
Touya’s experience within Pharma therefore positions him close to one of the most attractive structural opportunities in Aptar’s portfolio.
How much capital is Aptar already returning to shareholders?
Aptar returned $81 million through share repurchases and dividends during the second quarter and $212 million during the first six months of 2026. The distributions demonstrate that the company is generating enough cash to support both investment and direct shareholder returns.
That creates a capital-allocation challenge for the new CEO. Aptar has historically used bolt-on acquisitions to expand technology capabilities, particularly in Pharma, while also maintaining dividends and share repurchases.
Touya therefore needs to decide when incremental capital creates more value through acquisitions, manufacturing expansion or shareholder distributions.
His long tenure may help because he has experienced Aptar’s previous acquisition strategy from the operating side and can judge which technologies actually created commercial value after integration.
What does Stephan Tanda leave behind after nearly a decade as CEO?
Tanda joined Aptar in 2017 and oversaw significant portfolio expansion, operational improvement and approximately 20 bolt-on acquisitions and investments, with a majority concentrated in Pharma. He also expanded Aptar’s presence across emerging markets and strengthened its focus on sustainability and cost discipline.
That means Touya inherits a company considerably more exposed to high-value drug-delivery technologies than the one Tanda originally took over.
Tanda’s decision to remain an adviser through year-end gives the new CEO continuity across customer relationships, capital projects and acquisition integration while still establishing September 1 as a clear transfer of executive authority.
The board also appointed Touya as a director effective September 1, increasing the board from ten to eleven members. That gives him formal governance responsibility alongside his executive role.
What does Aptar stock performance say about expectations for the new CEO?
Aptar shares closed at $131.62 on August 31, down modestly for the session and approximately 2.3% lower than the August 24 level. The shares were also roughly 1.8% below their July 31 close, indicating that investors entered the CEO transition without a strong short-term momentum trend.
The 52-week range is approximately $103.23 to $146.91. At the August 31 close, Aptar was roughly 10% below the annual high but about 27% above the 52-week low.
That positioning reflects neither deep pessimism nor excessive optimism. Investors appear willing to credit the company’s pharmaceutical exposure but remain attentive to margin pressure and the relatively modest pace of core sales growth.
Touya therefore begins with a valuation that gives him room to create upside but does not assume the GLP-1, biologics and injectables opportunities will automatically translate into stronger earnings.
What should investors watch during Gael Touya’s first year?
Core sales growth is the first benchmark. Aptar’s second-quarter reported sales increased 6%, but underlying core growth was only 1%, making acceleration in organic demand important if the company wants to demonstrate that its portfolio is strengthening without relying heavily on acquisitions or currency.
The second benchmark is EBITDA margin. Returning from 20.7% toward the 22%-plus levels achieved previously would demonstrate that temporary pharmaceutical headwinds are easing and operating leverage is returning.
Pharma growth will provide the most strategically important indicator. Demand from GLP-1 therapies, biologics, injectables, vaccines and consumer healthcare needs to translate into enough incremental earnings to justify years of investment in the segment.
Gael Touya therefore inherits a business with a particularly clean strategic challenge. Aptar has already crossed $1 billion of quarterly sales and built exposure to several of the pharmaceutical industry’s fastest-growing categories.
His task is making sure record revenue becomes record-quality earnings rather than simply a larger top line.
Discover more from Business-News-Today.com
Subscribe to get the latest posts sent to your email.
